

North Central Cancer Treatment Group

N0177: A Phase I/II Trial of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Status Change – September 20, 2006

NOTICE OF STATUS CHANGE

Study 2 will re-open for 3 patients to Mayo (Rochester, Jacksonville, Arizona), the University of Virginia, and the University of Alabama at Birmingham at dose level 3E (600 mg OSI-774) effective **Wednesday, September 20, 2006**.

Please retain this notice with the protocol.